Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Enterprise Value (2016 - 2025)

Rocket Pharmaceuticals' Enterprise Value history spans 10 years, with the latest figure at -$300.3 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 19.35% year-over-year to -$300.3 million; the TTM value through Dec 2025 reached -$300.3 million, up 19.35%, while the annual FY2025 figure was -$300.3 million, 19.35% up from the prior year.
  • Enterprise Value for Q4 2025 was -$300.3 million at Rocket Pharmaceuticals, down from -$222.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$222.8 million in Q3 2025 and bottomed at -$680.2 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$381.0 million (2021), against an average of -$420.6 million.
  • The largest annual shift saw Enterprise Value tumbled 88.28% in 2021 before it surged 47.69% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$388.7 million in 2021, then grew by 8.32% to -$356.4 million in 2022, then dropped by 4.71% to -$373.2 million in 2023, then rose by 0.22% to -$372.3 million in 2024, then increased by 19.35% to -$300.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Enterprise Value are -$300.3 million (Q4 2025), -$222.8 million (Q3 2025), and -$271.5 million (Q2 2025).